In support of this notion, NAD+ supplementation has been found to enhance the tumor‐killing efficacy of T cells and the adoptive chimeric antigen receptor T (CAR‐T; Box 1) cell and anti‐PD1 immune checkpoint blockade response in mouse models [228, 234]. The gene discussed is PDCD1; the disease is neoplasm.